LSBio offers antibodies for multiple applications, many species, and in both conjugated and unconjugated forms. Each Antibody indicates the applications for which it has been tested, such as Western, ELISA, Flow, Immunohistochemistry on frozen (IHC-F) or formalin-fixed paraffin tissues (IHC-P). Subsets of these antibodies have also been extensively tested for their IHC applications.
The IHCplus™ Antibodies have been tested in IHC against a broad panel of normal human formalin-fixed paraffin-embedded (FFPE) tissue types and demonstrate excellent sensitivity and specificity for detecting the target protein.
The PathPlus™ Antibodies have undergone additional validation to evaluate their performance within a particular research area or application, such as cancer or neuroscience. The latest release of the LSBio PathPlus™ Cancer Antibodies, are a collection of best-in-class IHC reagents for the detection of 200 molecular pathology cancer targets. Future releases will expand on the number of antibodies to cancer targets, as well as introduce top performing antibodies within other key research areas.